BioSpace News Archive

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in 1x1 investor meetings at the Morgan Stanley 19th Annual Global Healthcare Conference.

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, announced that the company will participate in two upcoming investor conferences.

CohBar, Inc., a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the following investor conferences in September.

Enzo Biochem, Inc., a leading biosciences and diagnostics company, announced that management will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually from September 13th - 15th.

Immuneering Corporation, a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, announced that Company management will participate in two upcoming virtual investor conferences in September 2021.

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announced the Company will participate in two upcoming investor conferences.

Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 224,000 shares of Dynavax common stock as inducements to 8 newly-hired employees in connection with commencement of employment with the Company.

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI).

CooperCompanies announced financial results for its fiscal third quarter ended July 31, 2021.

Neurocrine Biosciences, Inc. announced that members of the management team will participate at the following virtual investor conferences.